Canopy Growth Corporation (NASDAQ: CGC) announced it will supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom through a deal with GROW Group U.K. Ltd., a manufacturer and distributor of prescribed cannabis-based medicines across Europe.

The products will be commercialized in the UK under Canopy Growth's Spectrum Therapeutics medical brand. The company described the arrangement as an initial launch of its portfolio products into the UK market.

"Expanding availability of our products into the UK is another step in growing our European medical cannabis business and broadening the international reach of our Canadian-grown flower," said Luc Mongeau, Chief Executive Officer of Canopy Growth.

The UK supply agreement follows the renewal of the European Union Good Manufacturing Practice (EU GMP) certification at Canopy Growth's Kincardine, Ontario cultivation facility, which the company said supports its ability to serve medical cannabis markets across Europe.

The announcement was based on information provided in a press release issued by the company.